| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
- Motesanib
-
-
2026-06-30
- CAS:453562-69-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- motesanib
-
- $15.00
-
2021-07-02
- CAS:453562-69-1
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Motesanib
-
- $1.00
-
2020-01-03
- CAS:453562-69-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kgs
|
| | Motesanib Basic information |
| Product Name: | Motesanib | | Synonyms: | CS-1108;AMG 706; AMG-706;N-(3,3-diMethylindolin-6-yl){2-[(4-pyridylMethyl)-aMino](3-pyridyl)}-carboxaMide;3-PyridinecarboxaMide, N-(2,3-dihydro-3,3-diMethyl-1H-indol-6-yl)-2-[(4-pyridinylMethyl)aMino]-;Motesanib Base;AMG-706(Motesanib);Motesanib (AMG-706) Base);motesanib | | CAS: | 453562-69-1 | | MF: | C22H23N5O | | MW: | 373.45 | | EINECS: | | | Product Categories: | API;Inhibitors;Antineoplastic | | Mol File: | 453562-69-1.mol |  |
| | Motesanib Chemical Properties |
| Melting point | 147-150°C | | Boiling point | 517.3±50.0 °C(Predicted) | | density | 1.251 | | storage temp. | Refrigerator | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | White powder solid. | | pka | 11.75±0.40(Predicted) | | color | Pale Yellow | | InChI | InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28) | | InChIKey | RAHBGWKEPAQNFF-UHFFFAOYSA-N | | SMILES | C1(NCC2C=CN=CC=2)=NC=CC=C1C(NC1=CC2=C(C=C1)C(C)(C)CN2)=O |
| | Motesanib Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3, PDGFR, c-Kit and Ret with IC50 of 2 nM/3 nM/6 nM, 84 nM, 8 nM and 59 nM, respectively. | | Uses | Motesanib is an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. | | Definition | ChEBI: Motesanib is a pyridinecarboxamide. | | in vivo | Motesanib (100 mg/kg) significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1 mg/kg and 4.9 mg/kg, respectively. Motesanib induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells[1]. Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models[2]. Motesanib treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen[3]. | | target | VEGFR1 | | IC 50 | VEGFR1: 2 nM (IC50); VEGFR2: 3 nM (IC50); VEGFR3: 6 nM (IC50) |
| | Motesanib Preparation Products And Raw materials |
|